Johnson & Johnson (JNJ) Earnings Heal Stock

Don't expect material headwinds to earnings from increasing inflationary pressure, says Damien Conover on Johnson & Johnson (JNJ). He and Lee Bohl recap JNJ earnings. They discuss how JNJ's earnings came in better-than-expected. They also note that JNJ's 3Q worldwide pharmaceutical sales came in at $13.21B. Lee also says that JNJ spends heavily on R&D and most of M&A spending goes toward acquiring companies with promising pipeline drugs. Tune in to find out more about the stock market today.

The Watch List

19 Oct 2022

SHARE

ON AIR
11:00 pm
Trading 360
replay
12:00 am
Fast Market
REPLAY
1:00 am
Trading 360
REPLAY
2:00 am
Next Gen Investing
REPLAY
education
3:00 am
Your First Trade
REPLAY
3:30 am
Trading 360
REPLAY
4:30 am
Next Gen Investing
REPLAY
education
5:30 am
Your First Trade
REPLAY
6:00 am
Fast Market
REPLAY
7:00 am
Futures
8:00 am
Morning Trade Live
10:00 am
Trading 360
11:00 am
Fast Market
12:00 pm
Next Gen Investing
1:00 pm
The Watch List
2:00 pm
Market On Close
3:30 pm
Market Overtime
REPLAY
4:00 pm
Trading 360
REPLAY
5:00 pm
Fast Market
REPLAY
6:00 pm
Next Gen Investing
REPLAY
7:00 pm
Market Overtime
REPLAY
education
7:30 pm
Your First Trade
REPLAY
8:00 pm
Trading 360
REPLAY
9:00 pm
Market Overtime
REPLAY
education
9:30 pm
Your First Trade
REPLAY
10:00 pm
Fast Market
REPLAY
ON AIR
11:00 pm
Trading 360
REPLAY

Get the Market Minute

Daily insights for every investor

coming soon

We are now

coming soon

We are now